Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on SAM. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel patent CN113825759A details a safe, scalable route to maytansinol using Grignard reagents, eliminating hazardous hydride reductions for reliable API intermediate supply.
Novel transaminase mutant CN113621592A enables 99% yield of L-glufosinate. Reduces cost and improves supply chain reliability for agrochemical intermediates.
Patent CN106497843B reveals high-purity biocatalytic route. Reduces costs and enhances supply chain reliability for diabetes drug intermediates.
Patent CN102816083B reveals high-purity Lacosamide intermediate synthesis with strict temperature control and improved yield for reliable supply chain.
High purity NAG synthesis via chitin hydrolysis. Cost-effective, scalable process for pharma and nutrition supply chains.
Patent CN116515782A reveals a novel amine dehydrogenase mutant for high-purity chiral amine alcohol production, offering significant cost and safety advantages.
Patent CN119823960B discloses mutants for L-glufosinate. Improves efficiency and purity for agrochemical intermediate manufacturing supply chains.
Patent CN110914417B reveals high-activity transaminase for chiral amine synthesis, offering cost reduction and supply chain reliability for pharmaceutical intermediates.
Patent CN109136311B reveals cost-effective SAM production. Adenosine substrate replaces ATP. Reliable supplier for pharma intermediates.
Patent CN105039450A reveals one-step enzymatic route. High purity, scalable process for reliable pharmaceutical intermediate supplier partners seeking significant cost reduction and efficiency.
Novel transaminase mutants for chiral amine production. Enhanced stability at 55°C and pH 10. Cost-effective biocatalysis for pharma intermediates.
Patent CN116064451B reveals high-activity transaminase mutant. Enables cost reduction in pharmaceutical intermediates manufacturing with scalable enzymatic processes.
Novel patent CN106957239A offers low-cost Lacosamide synthesis. High yield, mild conditions, scalable for reliable pharmaceutical intermediate supply chains.
Advanced enzymatic deracemization of L-glufosinate-ammonium via patent CN112410383B. Delivers superior purity and cost efficiency for global agrochemical supply chains.
Patent CN117070577A reveals dual-enzyme cascade for high-purity L-glufosinate. Enhances supply chain reliability and reduces manufacturing costs significantly.
Patent CN106399418A details a transaminase method for moxifloxacin side chain, offering high purity and cost reduction in pharma manufacturing.
Novel solid-phase synthesis method for Samoamide A ensures high purity and yield, offering cost reduction in peptide manufacturing and reliable supply chain solutions.
Novel patent CN118271200A enables efficient lacosamide synthesis without protecting groups ensuring supply chain stability and cost reduction for global pharmaceutical manufacturers.
Patent CN106699605B offers a safe methylation method for lacosamide intermediates ensuring high purity and scalable production for reliable pharmaceutical supply chains.
Novel two-step process avoids acid chlorides. Enhances supply chain reliability and cost reduction in pharmaceutical intermediate manufacturing.